首页> 美国卫生研究院文献>Viruses >Progress in the Production of Virus-Like Particles for Vaccination against Hepatitis E Virus
【2h】

Progress in the Production of Virus-Like Particles for Vaccination against Hepatitis E Virus

机译:用于乙型肝炎病毒的病毒样颗粒的生产中的进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hepatitis E virus (HEV), a pathogen that causes acute viral hepatitis, is a small icosahedral, quasi-enveloped, positive ssRNA virus. Its genome has three open reading frames (ORFs), with ORF1 and ORF3 encoding for nonstructural and regulatory proteins, respectively, while ORF2 is translated into the structural, capsid protein. ORF2 is most widely used for vaccine development in viral hepatitis. Hepatitis E virus-like particles (VLPs) are potential vaccine candidates against HEV infection. VLPs are composed of capsid subunits mimicking the natural configuration of the native virus but lack the genetic material needed for replication. As a result, VLPs are unable to replicate and cause disease, constituting safe vaccine platforms. Currently, the recombinant VLP-based vaccine Hecolin® against HEV is only licensed in China. Herein, systematic information about the expression of various HEV ORF2 sequences and their ability to form VLPs in different systems is provided.
机译:乙型肝炎病毒(HEV),导致急性病毒性肝炎的病原体是一个小型ICOSAHEDRAL,准封闭的阳性SSRNA病毒。其基因组具有三个开放的阅读框架(ORF),分别具有ORF1和ORF3,分别用于非结构和调节蛋白,而ORF2被翻译成结构,衣壳蛋白。 ORF2最广泛用于病毒性肝炎的疫苗发育。乙型肝炎病毒样颗粒(VLP)是针对HEV感染的潜在疫苗候选者。 VLP由胶囊亚基组成,模拟天然病毒的自然配置,但缺乏复制所需的遗传物质。结果,VLP无法复制和导致疾病,构成安全疫苗平台。目前,Refombinant VLP的疫苗Hecolin®对抗HEV仅在中国获得许可。这里,提供了关于各种HEV ORF2序列表达及其在不同系统中形成VLP的能力的系统信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号